Here you will find current external funding opportunities available for innovation and research projects.

If you are aware of funding oportunities that are not listed please email the detail to stees.ideas@nhs.net and they will be added to the website.

 

SME support to evaluate innovative medical technologies: round 3

The Office for Life Sciences (OLS) will work with Innovate UK, as part of UK Research and Innovation, to invest up to £1.5 million in innovation projects. These will be to support developers of innovative medical devices, diagnostics and regulated digital technology to evaluate their product in a real world clinical setting.

You can choose from 2 options:

  • Planning and preparation for a study. Project costs can be up to £50,000.
  • A study to collect clinical performance and cost-effectiveness data. Project costs can be up to £250,000.

All projects must be business led.

This competition aims to provide support for micro, small and medium-sized enterprises (SMEs). We are looking for studies that aim to develop an evidence base for products that address NHS priorities. Our support will allow companies to collect and analyse clinical performance and cost effectiveness data in an NHS setting.

You can work alone or collaborate with others as unfunded partners or sub-contractors. Only the lead partner can claim grant funding.

If your project’s total costs or duration fall outside of our eligibility criteria, you must provide justification by email to support@innovateuk.ukri.org at least 10 days before the competition closes. We will decide whether to approve your request.

Deadline: Wednesday 30th January 2019 at 1200hrs

Further information can be found here.

H2020: Mining big data for early detection of infectious disease threats driven by climate change and other factors - SC1-BHC-13-2019

Specific Challenge:

A range of factors is responsible for the (re-)emergence of infectious disease threats, including antimicrobial resistance, altering the epidemiology and spread of disease in a changing global environment. These include drivers such as climate change and associated environmental impacts, population growth, unplanned urbanisation and high mobility, as well as animal husbandry or intensive farming practices.

At the same time, tools for infectious disease diagnostics and surveillance are evolving rapidly, allowing for ever more accurate diagnosis in ever shorter time. The use of next generation sequencing combined with surveillance data, health registries and societal data from informal/non-traditional sources (e.g. social media) holds promise for improving individual and population health. Current advanced IT technologies offer the opportunity to integrate such big data sets and could enable the rapid and personalised treatment of infected patients, and bolster the detection, tracking and control of infectious disease outbreaks.

ScopeIt is expected that proposals develop:

  • the technology to allow the pooling, access, analysis and sharing of relevant data, including next generation sequencing;

  • the innovative bio-informatics and modelling methodologies that enable risk modelling and mapping; and

  • the analytical tools for early warning, risk assessment and monitoring of (re-)emerging infectious disease threats.

Proposals should be able to demonstrate the feasibility of such extended data mining for the purposes outlined above, as well as its European level added value. The ready-to-use analytical tools and services that are developed should be based on an assessment of the needs of potential end-users in the Member States and on European level, should as far as possible build on and be compatible with existing European initiatives, and should remain available for public use at the end of the project at a reasonable cost.

Proposals should be transdisciplinary and ensure an integrated One Health approach by linking data from a wide range of relevant sources depending on the infectious disease threat. These may include human (e.g. community, hospital or laboratory health services) and animal health surveillance, health registries, microbial and viral genomic data (including next generation sequencing), pathogen resistance data, mapping of vectors, climate and environmental data as well as societal data that are correlates of disease; possible sex and/or gender differences should be taken into account. Solutions for gaps in existing data (addressing both a lack in quality and quantity) should be proposed.

Solutions for interoperability between different data sources should be addressed and integrated. It is expected that quality-controlled data are shared in accordance to the general concepts of the FAIR principles. The use of harmonised protocols in collaboration with other actors is recommended for this purpose. Appropriate regulatory and governance mechanisms need to be foreseen, taking into account different data sharing needs, as well as data privacy and data security aspects for the different types of stakeholders providing and analysing data. The technology and tools developed should be functional outside of outbreaks (i.e. in "peace time"), so that all stakeholders involved develop a routine use of them. At the same time, flexibility is needed to enable adaptation to different outbreak contexts and situations. The proposal shall foresee, in case of public health emergencies, open access to data at the moment it is generated or no later than one month thereafter subject to any safeguards required to protect research participants and patients, in accordance with the relevant options in Article 29.3 of the Model Grant Agreement.

The use of advanced IT technologies like high performance computing, or geo-localisation data are anticipated. The use of European health research (e-)infrastructures such as those included under CORBEL is encouraged where relevant. The successful proposal(s) should foresee to consult with the end-users at both national (e.g. public health institutes) and European (e.g. ECDC, EFSA) level at key milestones of the project's timeline. If more than one proposal is selected, they are expected to collaborate. In addition, coordination will be needed with the selected proposal from the Horizon 2020 call topic SFS-36-2017 on the establishment of a European Joint Programme on One Health.

The Commission considers that proposals requesting a contribution from the EU of between EUR 12-15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Strengthened EU preparedness to address threats from (re-)emerging infectious disease threats, by making available the appropriate technology and tools for risk modelling and early threat detection, to support an appropriate public health response.

  • Contribution to the European One Health action plan against antimicrobial resistance.

  • Contribution to the digital transformation of health and care within the context of the EU Digital Single Market.

  • Contribution to achieving Sustainable Development Goal (SDG) 3 and specifically the targets on 1) combating epidemics, and 2) strengthening capacity for early warning and response to health risks.

  • Contribution to achieving of SDG 13 and specifically the targets on 1) integrating climate change measures into national policies, strategies and planning, and 2) improving education, awareness-raising and human and institutional capacity on climate change adaptation, impact reduction and early warning.

Deadline: Tuesday 16th April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: The Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health - SC1-BHC-28-2019

Specific ChallengeDespite the general acknowledgement by the scientific community that 'Genetics load the gun but environment pulls the trigger'' when it comes to the causation of major non-communicable diseases (NCDs)there is persistent uncertainty as to the global burden of disease attributable to environmental (including life-style and climatic) factors, including healthcare costs and negative economic impact. Deciphering the human exposome is a novel way of addressing the challenge to improve health and reduce the overall burden of disease. This will require improved knowledge of health risks, including combinations of several risk factors, and the mechanisms by which they affect health at different stages throughout the life course, including exposures in foetal life. Effective preventive action will need to be designed, building on knowledge of various risk factors, including exposure to pollutants in daily life, individual behaviour and the social context, taking into account gender issues.

Developing a Human Exposome Project would present a fundamental shift in looking at health, by moving research away from ‘one exposure, one disease’ understanding to a more complex picture upon which to build solid, cost-effective preventive actions and policies in the future. It would respond to the need for more complete and accurate individual-level exposure data in order to estimate the largely unknown environmental component of NCDs.

ScopeApplicants should take advantage of the last decade's rapid technological advances which have opened up new opportunities to collect, combine and analyse large data sets offering new possibilities to understand the contribution of environmental factors to the global health burden of common chronic diseases. Proposals should use innovative approaches to the systematic and agnostic identification of the most important environmental risk factors for the development of major NCDs across the life course (including in utero), leading to preventive interventions at the individual, group or population level and contribute to sustainable healthcare. Well-designed retrospective epidemiological studies may be included and proposals may envisage the creation of a prospective Europe-wide exposomics cohort and biobank, integrating behavioural, socio-economic factors and clinical records.

The following components should be considered: agnostic evaluation of the role of multiple and unknown exposures; assessment of individual exposure to multiple stressors; sensors that combine external exposure and health data measurements; integration of external exposome data with cross-omics responses and (epi)genetic data; systematic evaluation and simulations of the health impacts; socio-economic modelling and econometric analysis including ethical and sex/gender aspects where relevant; better data mining tools, including advanced statistical analysis of complex data and high-performance/high throughput computing and storage; a long-term host and a single shared data infrastructure, taking into account existing structures and ensuring open access to data generated.

Innovation and connections with industry are expected in the areas of sensor development (external exposome), omics technology and novel biomarker development (internal exposome), bioinformatics, and data processing and management. Proposals are expected to respond to a persistent or long-standing policy/regulatory need where the exposome approach would be useful to solve a scientific issue to underpin better regulation now or in the future (examples: indoor and outdoor air quality, waste, occupational health, noise).

In order to establish an overarching Human Exposome Project, an overall coordination mechanism between the projects funded will be required and will be added at the grant preparation stage to all selected proposals as a common work package. Grants awarded under this topic will be complementary. The respective options of Article 2, Article 31.6 and Article 41.4 of the Model Grant Agreement will be applied.

The Commission considers that a proposal requesting an EU contribution between EUR 8 to 12 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

  • Innovation in environmental health sciences, in particular for external and internal exposure assessments and data management.

  • Enabling researchers and policy makers to continuously include new knowledge in the policy making processes by using the toolbox to generate data and information.

  • Better prediction of disease risk by acquisition of new knowledge on the influence of external exposures on biological pathways at different life-stages and identification of early signs of health damage caused by environmental factors.

Deadline: Tuesday 16 April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: Regenerative medicine: from new insights to new applications - SC1-BHC-07-2019

Specific Challenge: Regenerative medicine offers hope for untreatable disease and the ageing population, improved quality of life and reduced medical costs. However, so far, regenerative medicine has not yet proved itself in the clinic beyond rare diseases or conditions of limited public health importance. With recent scientific discoveries opening up new approaches to regenerative medicine, the challenge is to use these to extend the regenerative approach to major diseases and conditions.

ScopeRegenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function. Projects should focus on innovative translational research to develop regenerative processes towards the ultimate clinical goal of addressing unmet clinical needs of large patient groups. Proposals should be based on new approaches such as genome editing or gene therapy, transdifferentiation or in vivo reprogramming, cell therapy and transplantation, 3D bioprinting, organoids or use of combined products (non-exhaustive list for illustrative purposes only). In all cases, proposals should explain in what way their approach is regenerative. Research on improved methods of tissue and organ transplantation is included on the condition that there is a clear regenerative step in the process. The project may focus on any step(s) on the innovation chain, from early testing and characterization of regenerative mechanisms to preclinical research, proof of concept or clinical trial. Sex and gender differences should be investigated, where relevant. Projects should include a section on the proposed therapy's exploitation potential, regulatory and commercialisation strategy and how it would be made available and delivered to patients.

The Commission considers that proposals requesting a contribution from the EU of between EUR 6 and 8 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact

  • Potential new regenerative therapies to address unmet clinical needs of large patient groups identified
  • Europe's position in translational regenerative medicine strengthened
  • New therapies for major human diseases and conditions, and new approaches for therapy taken further in the development pipeline.

Deadline: Tuesday 16th April 2019 at 1700 hrs (CET)

Further information can be found here.

H2020: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis - SC1-BHC-10-2019

Specific Challenge: We observe a progressive shift in routine diagnostics, and more particularly in personalised medicine practice, from a growing number of molecular tests to a next generation sequencing approach (NGS). NGS can provide insights on a person’s genetic susceptibility to disease, diagnostic information, and predictive indications about treatment outcome. It also allows to embrace simultaneously different molecular pathways of disease evolution and to identify actionable mutations in a patient for medical decision and further research. In addition, it requires less sample material than multiple tests and therefore reduces risk and inconvenience for patients. However, the introduction of NGS in clinical practice is hampered by its cost, the availability of proper NGS tests, and diagnostic errors resulting from insufficient quality assurance, technological bias and complex interpretation of data.

Scope: The objective is to implement NGS in routine diagnostics for personalised medicine and scale up demand-driven innovation for healthcare systems. This includes organisational, economical, technical and clinical aspects. It should lead to NGS tests, clinically validated procedures (including sex analysis), quality assurance schemes, tools and methods for data collection, management, analysis and interpretation, with a view to assist clinical decision-making and foster medical research and innovation. Transferability and cloud based NGS data analyses should be considered, as appropriate. Input from initiatives like the EJP Cofund on rare diseases and ERNs should be considered when relevant. Ethical issues should be addressed.

For grants awarded under this topic for Pre-Commercial procurement it is expected that results could contribute to European or international standards. Therefore, the respective option of Article 28.2 of the Model Grant Agreement will be applied.

The Commission considers that proposals requesting a contribution from the EU of between EUR 9 and 11 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Proposals of this topic should follow the specific requirements for pre-commercial procurement PCP supported by Horizon 2020 grants as set out in General Annex E of the WP.

Expected Impact:

  • New NGS platforms and use of NGS tests in routine diagnostics for personalised medicine.
  • Accepted new European standards and quality assurance schemes with respect to NGS.
  • Strengthening of implementation of personalised medicine and improved clinical decisions and health outcomes for the benefits of patients.
  • Contribution to the sustainability of healthcare systems.
  • Growth and benefit to the European industry, in particular SMEs.

Deadline: Tuesday 16 April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: Large Scale pilots of personalised & outcome based integrated care - SC1-DTH-11-2019

Specific Challenge: Senior people are statistically at greater risk of cognitive impairment, frailty and multiple chronic health conditions with consequences for their independence, their quality of life (and the one of their families) but also for the sustainability of health and social care systems. There is also increasing evidence that interactions with the environment play an important role in the evolution of the patient's health status and condition. The challenge is now to foster secure, scalable and robust digital solutions for integrated care which will:

  • Ensure a truly personalized delivery of health and social care, whilst supporting outcomes-based significant efficiency gains in health and care delivery.
  • Promote a shift towards outcome-based delivery of integrated (health and social) care, which can be realised in a realistic operational, organisational and financial setting.
  • Ensure trust of users and policy makers with regard to data access, protection and sharing.
  • Design flexible but replicable solutions with a potential for financial sustainability, large scale deployment and further business and job creation opportunities.

Scope: The scope of this topic is to foster the large-scale pilots for deployment of trusted and personalised digital solutions dealing with Integrated Care, with a view to supporting and extending healthy and independent living for older individuals who are facing permanently or temporarily reduced functionality and capabilities. This in turn is expected to contribute to a patient-centred and truly individualized strategy in order to develop trusted, robust and financially sustainable services potentially useable in any Member States and the Digital Single Market, and applicable to a very wide range of patient pathways. These approaches aim to enable people to remain independent as long as possible and prevent hospitalisation.

Expected outcomes are in priority:

  • Efficiency gains in terms of resource utilization and coordination of care.
  • Flexibility and replicability of service delivery patterns to combine personalization and large scale adoption of services with patient and citizen feedback.
  • Ensuring secure and efficient sharing and processing of all data and information involved in the supply chain at each step of data stream: access, protection, sharing, processing and storage.
  • Improvement of quality of life for the patient and his/her family and also of working conditions of all health care and social care providers involved in the supply chain, taking into account multi-disciplinary environment and constraints. Working conditions of professionals should cover in priority: work time management, quality of data/information exchange and multi-disciplinary coordination.

Outcome indicators should contribute to the assessment of the action regarding trust, recruitment, added value for the patient (in terms of quality of life) and cost-efficiency altogether.

  • Recruitment of professionals will be measured by the number of professionals registered as actual used compared with the number of professionals actually registered in the pilot site region.
  • Quality of life should be measured on the basis of commonly used questionnaires (like SF36) but also if required on the basis of specific disease-oriented measurement tools.
  • Measurement of cost-efficiency should be measured on the basis of work time information dedicated to each patient.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected Impact:

Proposals should provide measurable progress towards:

  • A common vision of technical prerequisites and framework to ensure users trust with regard to health and social data and information in IT supported environment, in line with existing EU data protection regulation (and if required with EU reflection on platforms).

  • An evidence-based minimum data set on key points of the pathway: Harmonisation, certification, approval labelling or reliable identification of adequate solutions for integrated care.

    • Clerical information: complete definition

    • Clinical information: generic definition.

  • Robust and reliable and replicable business models for IT supported solutions in a truly personalized and multi-disciplinary environment.

Deadline: Wednesday 24 April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: SC1-DTH-05-2019 Large scale implementation of digital innovation for health and care in an ageing society

Specific Challenge: An ageing population is increasing demand-side pressures on public health and social care providers across Europe. These pressures undermine the long-term sustainability of existing models for delivering care services to the ageing population.

The challenge is to scale up outcome-based innovative digital health and care solutions across EU borders through joining up actions in procurement of innovation. Digital health and social care solutions have been tested and have demonstrated success in smaller scale settings. However, despite cooperation initiatives amongst regions through INTERREG programmes [1]or the transfer of innovation schemes of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA)[2], large-scale deployment of digital health and care solutions across EU borders remains limited. There is a lack of collaborative efforts in public purchasing of innovative ICT-based solutions for active and healthy ageing and successfully engaging demand and supply sides in scaling up innovation. This is the case in particular for digital solutions integrating health, social or community care and informal care, IoT enabled independent living solutions[3] that allow the citizens to live safely and independently at home therefore avoiding institutionalisation, or tele-care solutions and tools supporting for self-care and person-centred care. Moreover, take-up of these ICT-based solutions by both public care providers as well as people in need for care is a crucial factor in successfully alleviating the demand-side pressures on public health and care provision. Supporting the public procurement of innovation helps public authorities by aggregating demand and sharing the inherent risks associated to deploying new innovative solutions that can be integrated with existing public health and care provision systems.

Scope: This topic will contribute to the Digital Single Market Strategy priorities on digital transformation of health and care (notably to the priority on user-centred integrated care), to the Scaling-Up Strategy[4] of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) and will support the EIP on AHA Reference Sites contribution to the Digital Single Market Strategy, notably the priority focusing on user-centred integrated care. The actions supported will target large-scale deployment of digital health and care solutions across different regions in Europe. In line with the priority actions of the EIP on AHA Scaling-up Strategy, the scope of this PPI is to specify, purchase and deploy ICT based solutions (made up of services and ICT products to enable the provision of services) for active and healthy ageing through a common supply and demand side dialogue, which can deliver sustainable, new or improved health and care services promoting patient feedback in which public procurement approaches for innovative solutions lead to improved outcomes. Proposals should:

  • Be driven by clearly identified procurement needs[5] of the participating organisations and building on a deep understanding of the needs of the ageing population, as well as the needs of the relevant health and care providers;
  • Support sustainable deployment of new or improved person-centred and outcome-based services promoting patient feedback by providers involved in the procurement of solutions for digital health and care providers, including networking of inpatient and outpatient care, nursing services and care homes;
  • Contribute to the creation of scalable markets across Europe in innovative solutions for active and healthy ageing;
  • Specify measures that will ensure the sustainability of solutions beyond the lifespan of the proposed project, notably taking into account levels of acceptance with users and professionals as well as health economics considerations.
  • Engage public and/or private procurers from each country participating (at national, regional or local level) that have responsibilities and budget control in the relevant area of care or supply of services;
  • Be based on a complete set of common specifications for end to end services;
  • Demonstrate that the implementation phase will reach "large scale" (i.e. sufficient scale to achieve statistical significance) through region-wide deployment across multiple regions of Europe;
  • Contribute to the use of interoperable solutions based on open platforms and take into account existing best practices and standardisation initiatives;
  • Provide robust safeguards to ensure compliance with ethical standards and privacy protections and take account of the gender dimension;
  • Contribute with good outcome-based practices that are impact measured according to the MAFEIP[6] methodology and can be made available for replication across other regions (e.g. "detailed plans" for larger scale sustainable uptake of innovative solutions for active and healthy ageing, reference material and guidelines, manuals and education materials) through the EIP on AHA innovative practices repository.
  • Contribute to the development of national strategies to stimulate the procurement of digital innovation for health and care services based on the outcomes achieved at national level.

The European Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 5 million would allow this specific challenge to be addressed appropriately through PPI. This does not preclude submission and selection of proposals requesting other amounts.

Proposals of this topic should follow the specific requirements for innovation procurement PPI supported by Horizon 2020 grants as set out in General Annex E of the WP.

Expected impact:The proposal should provide appropriate indicators to measure its progress and specific impact in the following areas:

  • Growing awareness and successful use of public procurement to boost ICT innovation applied to integrated care and active and healthy ageing, implemented across the whole chain of care ultimately benefiting the growing ageing population across Europe;
  • Contribution with data and experiences to regulatory and legislative process development addressing potential barriers to procurement of innovative solutions for active and healthy ageing;
  • Contribution of an open and comprehensive socio-economic evidence base for ICT investments in the field that can support the development of sustainable business models (e.g. cost-benefit analysis, increased efficiency of health and care systems, impact assessments, return on investments, quality of life improvements for users, ethics, safety gain and user satisfaction);
  • Support initiatives on interoperability and standardisation that can contribute to defragmentation of the market for ICT based active and healthy ageing solutions;
  • Creation of economic boundary conditions that can support long-term sustainability of health and care systems and emergence of new business models to develop ICT innovation for active and healthy ageing in Europe;
  • Support forward-looking, concerted public-sector investment strategies that benefit from joint approaches across different regions;
  • Create new opportunities for market uptake and economies of scale for the supply side for ICT based solutions and services for active and healthy ageing in a Digital Single Market for Europe.
  • Contribute to inform policy measures that foster the take-up of ICT solutions for active and healthy ageing.

Deadline: Wednesday 24 April 2019 at 1700 hrs (CET)

Further information can be found here.

 

H2020: SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment

Specific Challenge: Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of genetic tests, timely diagnosis and effective treatment has created the impression of cancer being a chronic disease that can be cured. However, often rather aggressive treatment, psychological stress (anxiety and depression) can cause physical and psychological problems that may cause long-term after-cure consequences such as similar or other types of cancer, other types of (chronic) diseases and affect the quality of life of a patient. Therefore, the importance of addressing and, if possible, preventing long-term effects of cancer treatment is growing. In addition to patient-reported outcomes such as functional status, symptoms intensity and frequency, multiple domains of well-being and overall satisfaction with life, the use of big data can bring valuable information for monitoring health status and quality of life after the cancer treatment. Big Data can provide new opportunities to define statistical and clinical significance, but present also challenges as it requires specific analytical approaches.

Scope: Proposals should focus and deliver on how to better acquire, manage, share, model, process and exploit big data using, if appropriate, high performance computing to effectively monitor health status of individual patients, provide overall actionable insights at the point of care and improve quality of life after the cancer treatment. Relevant solutions include for example systems for determining and monitoring (taking also in account gender differences) the combined effects of cancer treatment, environment, lifestyle and genetics on the quality of life, enabling early identification of effects that can cause development of new medical conditions and/or impair the quality of life. Proposals preferably address relevant health economic issues, use patient reported outcome and experience measures (PROMs and PREMs) and take into account the relevant social aspects of health status and quality of life after cancer treatment. Integrated solutions should include suitable approaches towards security and privacy issues.

Information can be collected from traditional sources of health data (cohorts, comprehensive electronic health records or clinical registries, incl. genetic data, validated biomarkers for remission), from new sources of health data (mobile health apps and wearables) and from sources that are usually created for other purposes such as environmental data.

It is important to assure ethical aspects of data, confidentiality, and anonymity of data transfer and engagement of those who collect/code such data in its analysis and interpretation, in order to avoid misinterpretation and inappropriate conclusions by using proper annotation methodologies of the data. Involvement of those who work within healthcare systems, patients, family and relatives, and the general public is needed.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Participation of SMEs is encouraged.

Expected Impact: The proposal should provide appropriate indicators to measure its progress and specific impact in the following areas:

  • Mapped comprehensive big data in a reachable and manageable way by applying principles for sharing and reusability, creating a network of knowledge by linking translation tools, heterogeneous data sources and biomedical texts for monitoring health status and quality of life after the cancer treatment;
  • Emerging data driven analytics and advanced simulation methods to study causal mechanisms and improve forecasts of ill-health, identification of disease trajectories and relapse;
  • Better and faster means of high quality response to prevent or timely address development of new medical conditions and/or improve the quality of life;
  • Better knowledge for improved patient counselling as well as to improve follow-up of patients;
  • Novel information on health maintenance, onset and course of medical conditions with a view to optimise prevention and treatment;
  • Evidence base for the development of policy strategies for prevention, early diagnosis, therapies as well as addressing health inequalities, support to patient registries at national level;
  • Improved quality of life after cancer treatment, strengthening personal confidence and enhancing employability;
  • Preventative strategies are established which have a real effect of reducing the occurrence of health disorders and co-morbidities associated with cancer treatment.

Deadline: Wednesday 24th April 2019 at 1700 hrs (CET)

Further information can be found here.

Wellcome Trust - Innovator Award

Up to £500,000 available for up to 24 months to support researchers who are transforming great ideas into healthcare innovations that could have a significant impact on human health. The current focus areas are mental health, neurological disorders and neglected tropical diseases (although applications from other areas may be considered).

Deadline: Ongoing

Further information can be found here.

NESTA - Impact Investment Fund

The Fund invests between £150k and £1m in social ventures developing innovations that tackle the major challenges faced by older people, children and communities in the UK. An experienced team of sector experts, venture capitalists, impact investors and evaluators backed by Nesta, provide expertise and guidance, helping companies to grow their reach, demonstrate their impact and become financially sustainable.

Deadline: Ongoing

Further information can be found here.